Atomoxetine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Attention Deficit Hyperactivity Disorder
Conditions
Attention Deficit Hyperactivity Disorder
Trial Timeline
Sep 1, 2008 → Sep 1, 2010
NCT ID
NCT00760747About Atomoxetine
Atomoxetine is a approved stage product being developed by Eli Lilly for Attention Deficit Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00760747. Target conditions include Attention Deficit Hyperactivity Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01177943 | Phase 1 | Completed |
| NCT00969618 | Phase 3 | Completed |
| NCT00760747 | Approved | Completed |
| NCT00687609 | Approved | Terminated |
| NCT00636818 | Phase 2 | Completed |
| NCT00530335 | Phase 2 | Completed |
| NCT00471354 | Approved | Completed |
| NCT00918567 | Approved | Completed |
| NCT00299234 | Approved | Terminated |
| NCT00320528 | Phase 3 | Completed |
| NCT00252278 | Approved | UNKNOWN |
| NCT00255138 | Phase 3 | Withdrawn |
| NCT00953862 | Pre-clinical | Completed |
| NCT00191633 | Approved | Completed |
| NCT00286949 | Pre-clinical | Completed |
| NCT00488163 | Approved | Completed |
| NCT00191737 | Phase 3 | Completed |
| NCT00191516 | Phase 3 | Completed |
| NCT00191880 | Phase 3 | Completed |
| NCT00191035 | Approved | Completed |
Competing Products
20 competing products in Attention Deficit Hyperactivity Disorder